ScreenPoint Medical has raised $28 million in a Series C financing. New York-based Insight Partners led the round, with support from existing investors, including ScreenPoint Medical's founders Siemens Healthineers and Oost NL, and participation from the U.S. University Radiology Group (URG). ScreenPoint Medical is a spin-off of the Radboudumc.
ScreenPoint Medical is an AI technology company developing advanced image recognition and machine learning software to improve early detection of breast cancer. The new funding will be used by the company to accelerate the commercial growth of the company's Transpara AI software and improve the early diagnosis of breast cancer. One in eight women will develop breast cancer in their lifetime and early detection is the best way to increase survival rates. The investment will enable further research & development, as well as an expansion of the product portfolio.
Expansion in the US
"We are excited about this funding and the opportunity to work with the Insight Partners team to further scale the company," said Nico Karssemeijer, CEO of ScreenPoint Medical. "We are also pleased with URG's participation in this round, which shows confidence in the technology we are bringing to market. The practice of breast imaging is different in the US than in the EU. Collaboration with URG provides clinical expertise that is extremely valuable for further expansion in the US. This round puts ScreenPoint Medical in an excellent position to become the leading provider of AI-driven breast imaging solutions."
Source: ScreenPoint Medical
Related news items
Dutch-Nordic Alliance for Precision Cancer Medicine launched26 November 2021
The Nordic countries (Denmark, Sweden, Norway, and Finland) are together setting up national clinical precision cancer trials modelled on the very successful DRUP trial in the Netherlands.read more
New anti-inflammatory drugs increase risk of fungal infection22 November 2021
Investigators at the Department of Internal Medicine / Infectious Diseases and Dermatology demonstrate worldwide side effects of certain so-called biologics using four different research approachesread more
Million Euros to develop therapy against cancer metastasis in bones22 November 2021
In the PlatiBone project, researchers Sander Leeuwenburgh and Sandra Heskamp will test new drugs that combine diagnostics, chemotherapy and radiationread more
Survey of patients to address knee pain from removed meniscus19 November 2021
Patients with persistent knee pain after meniscus removal can participate at three locations in the Netherlands in the AIR2 study by ATRO Medical, a spin-off of the Radboudumc and DSM.read more